There are currently 1094 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Serial Amnioinfusions As Regenerative Therapy for Pulmonary Hypoplasia
NCT03723564
Recruiting
Congenital lower urinary tract obstruction (LUTO) is a heterogeneous group of congenital anomalies that lead bladder outlet obstruction. If a complete obstruction is present, the perinatal mortality is estimated to be as high as 90% because of severe pulmonary hypoplasia due to the lack of amniotic fluid. Survivors have significant risk of renal impairment (90%) requiring dialysis or renal transplantation if no fetal intervention is performed. Renal agenesis is the congenital absence of one or... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/31/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Renal Failure Congenital, Congenital Renal Anomaly Nos, Renal Agenesis and Dysgenesis, Lower Urinary Tract Obstructive Syndrome
Register for Updates
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737
Recruiting
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Advanced Solid Tumor, FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma
Register for Updates
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II
NCT05462587
Recruiting
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Gender:
ALL
Ages:
Between 6 months and 75 years
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leukocyte Adhesion Deficiency
Register for Updates
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II
NCT05754450
Recruiting
The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
Gender:
ALL
Ages:
Between 6 months and 75 years
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leukocyte Adhesion Deficiency
Register for Updates
A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
NCT05889988
Recruiting
Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Breast Neoplasm
Register for Updates
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708
Recruiting
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Register for Updates
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
NCT05184569
Recruiting
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/28/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Semantic Dementia
Register for Updates
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT06014255
Recruiting
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Prostate Cancer
Register for Updates
A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects
NCT05553132
Recruiting
The purpose of this research study it to gather information on the safety and side effects of treating cartilage defects with autologous cartilage cells mixed with allogeneic adipose-derived mesenchymal stem cells (AMSCs) in a fibrin glue.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/22/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Cartilage Defect
Register for Updates
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02977780
Recruiting
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib * Temozolomide (temodar) * Neratinib * CC115 * QBS10072S
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Glioblastoma
Register for Updates
Improving Implementation of Evidence-based Approaches and Surveillance to Prevent Bacterial Transmission and Infection
NCT04600973
Recruiting
Surgical site infections (SSIs) are associated with increased patient morbidity, mortality, and healthcare costs. ESKAPE (Enterococcus, S. aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter spp.) pathogens are particularly pathogenic because they have increased capacity to acquire resistance and virulence traits. The investigators have proven that a multifaceted program involving improved basic perioperative preventive measures can generate substantial reductions in S. aureus trans... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Infection
Register for Updates
Perform Humeral System Study
NCT05067543
Recruiting
This study is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up study, which is designed to collect safety and performance data at baseline, surgery, immediate post-op and annually through 10 years post-operation. Data collected from this study will be used for purposes, including but not limited to, Post-Market Surveillance, peer-reviewed publications, education materials, regulatory submissions, and/or product development.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Osteoarthritis Shoulder, Avascular Necrosis, Post-traumatic Arthrosis of Other Joints, Shoulder Region, Rotator Cuff Tear Arthropathy
Register for Updates